Pharmigene, Inc.
Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test… Read more
Pharmigene, Inc. (7595) - Total Liabilities
Latest total liabilities as of June 2025: NT$653.79 Million TWD
Based on the latest financial reports, Pharmigene, Inc. (7595) has total liabilities worth NT$653.79 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharmigene, Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Pharmigene, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharmigene, Inc. Competitors by Total Liabilities
The table below lists competitors of Pharmigene, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Motorsport Gaming Us LLC
NASDAQ:MSGM
|
USA | $3.31 Million |
|
Poxel SA
PA:POXEL
|
France | €66.41 Million |
|
Metallis Resources Inc
OTCQB:MTLFF
|
USA | $335.99K |
|
Kintech Electronics Co Ltd
TWO:6210
|
Taiwan | NT$84.24 Million |
|
H.Pio Co. Ltd.
KQ:357230
|
Korea | ₩69.98 Billion |
|
St-Georges Eco-Mining Corp
OTCQB:SXOOF
|
USA | $6.87 Million |
|
Xilam Animation
PA:XIL
|
France | €41.04 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Pharmigene, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharmigene, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharmigene, Inc. (2019–2024)
The table below shows the annual total liabilities of Pharmigene, Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$654.08 Million | +8.50% |
| 2023-12-31 | NT$602.85 Million | +1254.15% |
| 2022-12-31 | NT$44.52 Million | +20.65% |
| 2021-12-31 | NT$36.90 Million | -8.55% |
| 2020-12-31 | NT$40.35 Million | -2.71% |
| 2019-12-31 | NT$41.48 Million | -- |